Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors

Journal of Clinical Oncology

Volumn 33, Issue 29, 2015, Pages 3227-3234

  Hayes, D Neil ^a   Van Waes, Carter ^b   Seiwert, Tanguy Y ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; GENE MUTATION; GENETIC VARIABILITY; HEAD AND NECK CANCER; HUMAN; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS DNA CELL DNA INTERACTION; WART VIRUS; ADVERSE EFFECTS; CARCINOMA, SQUAMOUS CELL; COMPLICATION; DISEASE COURSE; GENETICS; HEAD AND NECK NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SMOKING; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SMOKING;

EID: 84944245456     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.1086     Document Type: Review

References (63)

1. Cancer Genome Atlas Network: Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517: 576-582, 2015
2. Gymnopoulos M, Elsliger MA, Vogt PK: Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 104: 5569-5574, 2007
3. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35, 2010
4. Abogunrin S, Di Tanna GL, Keeping S, et al: Prevalence of human papillomavirus in head and neck cancers in European populations: A metaanalysis. BMC Cancer 14: 968, 2014
5. Jiron J, Sethi S, Ali-Fehmi R, et al: Racial disparities in human papillomavirus (HPV) associated head and neck cancer. Am J Otolaryngol 35: 147-153, 2014
6. López RV, Levi JE, Eluf-Neto J, et al: Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection. Cancer Causes Control 25: 461-471, 2014
7. Deschler DG, Richmon JD, Khariwala SS, et al: The "new" head and neck cancer patient-young, nonsmoker, nondrinker, and HPV positive: Evaluation. Otolaryngol Head Neck Surg 151: 375-380, 2014
8. Gillison ML, Zhang Q, Jordan R, et al: Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30: 2102-2111, 2012
9. Huang SH, Xu W, Waldron J, et al: Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol 33: 836-845, 2015
10. Keck MK, Zuo Z, Khattri A, et al: Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res 21: 870-881, 2015
11. Jordan RC, Lingen MW, Perez-Ordonez B, et al: Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36: 945-954, 2012
12. Seiwert T. Accurate HPV testing: A requirement for precision medicine for head and neck cancer. Ann Oncol 24: 2711-2713, 2013
13. Dreyer JH, Hauck F, Oliveira-Silva M, et al: Detection of HPV infection in head and neck squamous cell carcinoma: A practical proposal. Virchows Archiv 462: 381-389, 2013
14. Schlecht NF, Brandwein-Gensler M, Nuovo GJ, et al: A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Modern Pathol 24: 1295-1305, 2011
15. Boyer SN, Wazer DE, Band V: E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitinproteasome pathway. Cancer Res 56: 4620-4624, 1996
16. Liang C, Marsit CJ, McClean MD, et al: Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res 72: 5004-5013, 2012
17. Chai RC, Lambie D, Verma M, et al: Current trends in the etiology and diagnosis of HPV-related head and neck cancers. Cancer Med 4: 596-607, 2015
18. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 354: 567-578, 2006
19. Curran D, Giralt J, Harari PM, et al: Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25: 2191-2197, 2007
20. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11: 21-28, 2010
21. Machiels J, Licitra LF, Haddad RI, et al: Afatinib versus methotrexate (MTX) as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy: Primary efficacy results of LUX-Head & Neck. Ann Oncol 25: 1-41, 2014
22. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al: Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open- label phase 3 randomised trial. Lancet Oncol 14: 697-710, 2013
23. Fayette J, Wirth LJ, Oprean C, et al: Randomized phase II study of MEHD7945A (MEHD) vs cetuximab (Cet) in 2nd-line recurrent/metastatic squamous cell carcinoma of the head & neck. Ann Oncol 25: Iv340-iv356, 2014
24. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 359: 1116-1127, 2008
25. Bonner JA, Harari PM, Giralt J, et al: Association of human papillomavirus (HPV) and p16 status with efficacy and safety data in the phase III radiotherapy (RT)/cetuximab (cet) registration trial for locoregionally advanced squamous cell carcinoma of the head and neck (LASCCHN). Ann Oncol 25: Iv340- iv356, 2014
26. Cmelak A: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). J Clin Oncol 32: 385s, 2014 (abstr LBA6006)
27. Seiwert TY, Zuo Z, Keck MK, et al: Integrative and comparative genomic analysis of HPV-positive and HPV- negative head and neck squamous cell carcinomas. Clinical Clin Cancer Res 21: 632-641, 2015
28. Agrawal N, Frederick MJ, Pickering CR, et al: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157, 2011
29. Chung CH, Guthrie VB, Masica DL, et al: Genetic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol 26: 1216-1223, 2015
30. Pickering CR, Zhang J, Yoo SY, et al: Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Disc 3: 770-781, 2013
31. Stransky N, Egloff AM, Tward AD, et al: The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160, 2011
32. Hayes DN, Kim WY: The next steps in nextgen sequencing of cancer genomes investigation. Clin Invest 125: 462-468, 2015
33. Lamlertthon W, Hayward MC, Hayes DN: Emerging technologies for improved stratification of cancer patients: A review of opportunities, challenges, and tools. Cancer J 17: 451-464, 2011
34. Meyerson M, Gabriel S, Getz G: Advances in understanding cancer genomes through secondgeneration sequencing. Nat Rev Genet 11: 685-696, 2010
35. Smeets SJ, Braakhuis BJ, Abbas S, et al: Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25: 2558-2564, 2006
36. Chung GT, Lou WP, Chow C, et al: Constitutive activation of distinct NF-kappaB signals in EBVassociated nasopharyngeal carcinoma. J Pathol 231: 311-322, 2013
37. Eliopoulos AG, Dawson CW, Mosialos G, et al: CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: IInvolvement of TRAF3 as a common mediator. Oncogene 13: 2243-2254, 1996
38. Hacker H,, Tseng PH, Karin M: Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 11: 457-468, 2011
39. Karim R, Tummers B, Meyers C, et al: Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Path 9: E1003384, 2013
40. Oganesyan G, Saha SK, Guo B, et al: Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439: 208-211, 2006
41. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619, 2006
42. Capelletti M, Dodge ME, Ercan D, et al: Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res 20: 6551-6558, 2014
43. Yuan L, Liu ZH, Lin ZR, et al: Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer Biol Ther 15: 1613-1621, 2014
44. Di Stefano AL, Fucci A, Frattini V, et al: Detection, characterization and inhibition of FGFRTACC fusions in IDH wild type glioma. Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-2199 [epub ahead of print on January 21, 2015]
45. Henderson S, Chakravarthy A, Su X, et al: APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7: 1833-1841, 2014
46. Burns MB, Temiz NA, Harris RS: Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45: 977-983, 2013
47. Roberts SA, Lawrence MS, Klimczak LJ, et al: An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45: 970-976, 2013
48. Dogan S, Shen R, Ang DC, et al: Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 18: 6169-6177, 2012
49. Parfenov M, Pedamallu CS, Gehlenborg N, et al: Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A 111: 15544-15549, 2014
50. Akagi K, Li J, Broutian TR, et al: Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 24: 185-199, 2014
51. Finn RS, Crown JP, Lang I, et al: The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2- negative, advanced breast cancer (PALOMA-1/ TRIO-18): A randomised phase 2 study. Lancet Oncol 16: 25-35, 2015
52. Gross AM, Orosco RK, Shen JP, et al: Multitiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet 46: 939-943, 2014
53. Rizvi NA, Mazières J, Planchard D, et al: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 16: 257-265, 2015
54. Walter V, Yin X, Wilkerson MD, et al: Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PloS One 8: E56823, 2013
55. Chung CH, Parker JS, Karaca G, et al: Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5: 489-500, 2004
56. Morris LG, Kaufman AM, Gong Y, et al: Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet 45: 253-261, 2013
57. Nola S, Daigaku R, Smolarczyk K, et al: Ajuba is required for Rac activation and maintenance of E-cadherin adhesion. J Cell Biol 195: 855-871, 2011
58. Sen GL, Boxer LD, Webster DE, et al: ZNF750 is a p63 target gene that induces KLF4 to drive terminal epidermal differentiation. Dev cell 22: 669-677, 2012
59. Wakabayashi N, Shin S, Slocum SL, et al: Regulation of notch1 signaling by nrf2: Implications for tissue regeneration. Sci Signal 3: Ra52, 2010
60. Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525, 2012
61. Kawasaki Y, Okumura H, Uchikado Y, et al: Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Annals Surg Oncol 21: 2347-2352, 2014
62. Shibata T, Kokubu A, Gotoh M, et al: Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135: 1358-1368, 2008
63. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43-49, 2013